A combination of two or more unhealthy lifestyle factors is associated with impaired physical and mental health in patients with spondyloarthritis: a cross-sectional study

Elisabeth Mogard1*, Ann Bremander2,3,4 and Emma Haglund2,3,6

Abstract

Background: There is increasing knowledge of how individual lifestyle factors affect patients with spondyloarthritis, while studies exploring the combination of unhealthy lifestyle factors are lacking. Thus, our aim was to study the frequency of two or more unhealthy lifestyle factors and their associations with physical and mental health in patients with spondyloarthritis (SpA).

Methods: A population-based postal survey involving questions on lifestyle factors was completed by 1793 patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA), and undifferentiated spondyloarthritis (USpA). Self-reported physical activity, body mass index, and tobacco use were respectively dichotomized as “healthy” or “unhealthy”, summarized for each patient and stratified into four groups (0–3; 0 = no unhealthy lifestyle factors). Group comparisons were performed with Chi-squared tests, and associations with physical and mental health outcomes were performed with analysis of covariance and logistic regression analysis.

Results: Out of 1426 patients (52% women) with complete information for all studied lifestyle factors, 43% reported ≥ two unhealthy lifestyle factors—more frequently patients with PsA (48%) than AS (39%) or USpA (38%)—and with no difference between women and men (p = 0.399). Two or more unhealthy lifestyle factors were associated with worse health-related quality of life, disease activity, physical function, pain, fatigue, anxiety, and depression, adjusted for age and SpA-subgroup. If an unhealthy level of physical activity was one of the two unhealthy lifestyle factors, patients reported worse health outcomes.

Conclusion: Reporting two or more unhealthy lifestyle factors were associated with worse physical and mental health in patients with SpA. This highlights the need to screen for a combination of unhealthy lifestyle factors and offer individualized coordinated interventions, and tailored coaching to support behavioral change, in order to promote sustainable health.

Keywords: Ankylosing spondylitis, Psoriatic arthritis, Spondyloarthropathy, Physical activity, Body mass index, Overweight/obesity, Tobacco, Smoking, Health-related quality of life

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
prevented or delayed by adhering to a healthy lifestyle [1–3]. In the general population, the negative impact of having one unhealthy lifestyle factor, such as not meeting the recommendations for physical activity, a healthy diet, or tobacco usage is well established. More recent studies have reported that the combined effect of more than one unhealthy lifestyle factor further increases the risk of certain comorbidities [4, 5] and overall morbidity [6]. Today, numerous studies support the fact that physical activity and cardiorespiratory fitness (CRF) have a strong inverse association with CVD and overall mortality [7] and, according to the American Heart Association, CRF may be an even stronger predictor of mortality, as compared to traditional risk factors [8]. Increasing amounts of physical activity and higher CRF have also been reported to improve components of metabolic syndrome [9], and CRF has been proposed to be more significant than obesity to long-term health [7]. In patients with chronic inflammatory arthritis (CIA), such as spondyloarthritis (SpA), an even higher risk for CVD has been reported [10–12], and both chronic inflammation and modifiable risk factors, including lifestyle factors are considered to play a part in this [13, 14].

SpA comprise a group of CIA with similar clinical features and include, among others, ankylosing spondylitis (AS), psoriatic arthritis (PsA), and undifferentiated spondyloarthritis (USpA). Based on the main symptoms, the diseases can also be classified in axial or peripheral SpA [15, 16]. In the clinical setting diagnoses are set according to the International Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10), as there are no universal diagnostic criteria developed for SpA.

The European Alliance of Associations for Rheumatology (EULAR) has recently incorporated lifestyle advice regarding physical activity and diet to existing advice on disease control, risk assessment, and smoking cessation in the updated recommendations for CVD risk management in CIA [17]. However, many patients with SpA do not meet the required level of physical activity to promote health, as recommended by WHO [18, 19], and obesity (Body Mass Index: BMI ≥ 30 kg/m²) [20], used as a proxy for an unhealthy diet, is more prevalent in patients with SpA than in the general population [21, 22]. Several studies have explored the impact of modifiable lifestyle factors, such as physical inactivity, obesity, and smoking in patients with SpA, and found associations with higher disease activity, lower physical function, and worse health-related quality of life (HRQoL) [19, 21, 23–26]. Obesity and smoking have also been associated with poor treatment response [23, 24, 27] and pain [28].

although there is increasing knowledge regarding individual lifestyle factors in patients with SpA, studies exploring unhealthy lifestyle factors and their combined effect on health are lacking. Such studies could be of importance in enhancing knowledge and informing healthcare professionals’ screening for cardiovascular risk and support of lifestyle changes in patients with SpA. In addition, health behaviours may be better captured if combined, rather than individual, lifestyle factors are studied [5]. Thus, our aim was to study the frequency of unhealthy lifestyle factors in a well-known SpA cohort, and the associations between two or more unhealthy lifestyle factors and physical and mental health. We also wanted to study the impact of being physically active in relation to the other lifestyle factors investigated.

Methods

Design

A cross-sectional study based on a postal questionnaire survey.

Study population

The SpAScania cohort: all patients with diagnostic codes for SpA, who were identified through the Skåne Healthcare Register (SHR) between 2003 and 2007. In the region of Skåne, Sweden, all health care visits (inpatient and outpatient) are registered in SRH. The register includes information about the healthcare provider, the date of visit, and diagnostic codes according to the International Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). The ICD-10 codes in SpAScania had to be set by either a specialist in rheumatology or internal medicine at one visit or by any other physician in primary or secondary care on two separate visits. This was done to ensure higher specificity of the SpA diagnoses, rendering a more strict criterion. More details about SHR, allocation and validation of the ICD-10 diagnoses in the SpAScania cohort can be found elsewhere [29]. A baseline questionnaire was sent to the SpAScania cohort in 2009, with a second follow-up questionnaire in 2011 (response rate 58%). In the present study, all respondents to the follow-up (2011) questionnaire who were ≥ 20 years of age and had an ICD-10 diagnosis corresponding to AS, PsA, or USpA were included (n = 1793). Ethical approval was granted by the Regional Ethics Committee in Lund, Sweden (Dnr 301/2007, 406/2008, 2011/547 and 2013/128), and informed written consent was obtained from all patients, in accordance with the Declaration of Helsinki.

The questionnaires

The whole survey was in Swedish and included several commonly used, well-validated patient-reported questionnaires to evaluate physical and mental health, and HRQoL. Information regarding age, sex, and ICD-10 diagnosis was obtained from the SHR, and symptom
duration (years), pain, fatigue, height, weight, physical activity level, and tobacco habits were obtained from the questionnaires.

**Lifestyle factors**
In this study, self-reported moderate-intensity aerobic physical activity (MPA) and vigorous-intensity aerobic physical activity (VPA) were captured by the International Physical Activity Questionnaire (IPAQ), short form (Swedish) [30]. The IPAQ has been found to have acceptable validity [31]. A combined total score for MPA and VPA was computed (MVPA) by summarizing the total number of minutes (based on intensity, duration, and frequency), as recommended by guidelines for data processing and analysis from the IPAQ Research Committee [30]. BMI; (kg/m²), here used as a proxy for an unhealthy diet, was categorized as underweight; < 18.5, normal weight; 18.5–24.9, overweight; 25–29.9, and obesity ≥ 30) [20]. Questions regarding tobacco as recommended by the Swedish National Board of Health and Welfare [32], included smoking and/or snuff/snus habits and were reported as never, past, or present usage. Patients who did not report health-enhancing levels of physical activity (HEPA; MPA ≥ 150 min/week or VPA ≥ 75 min/week, or a combination of MPA and VPA) [33], or who had a BMI ≥ 25 kg/m², or reported present usage of tobacco, were classified as “unhealthy”; all the others were classified as “healthy”. The number of unhealthy lifestyle factors was summarized for each patient and stratified into four groups (scoring 0–3, where 0 = no unhealthy lifestyle factors).

**Additional assessments**
HRQoL was assessed with the EuroQol-five dimensions, three level version (EQ-5D-3L), ranging from 0–1, where 1 = complete health [34]. Disease activity and physical function were assessed with disease-specific instruments for patients with SpA; the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [35] and the Bath Ankylosing Spondylitis Functional Index (BASFI) [36], with total scores for the various BAS-indices ranging from 0 (best) to 10 (worst). To assess pain and fatigue numerical rating scales (NRS) were used, ranging from 0 (no pain/fatigue) to 10 (worst possible pain/fatigue). The Hospital Anxiety and Depression scale (HADs) [37] was used for assessments of anxiety and depression. Each subscale consists of seven items, and the range is from 0 to 21 (no distress–maximum distress).

**Statistics**
Baseline characteristics for the SpA subgroups were presented with mean and standard deviation (SD), and Chi-squared tests were used for group comparisons of proportions. Comparisons between groups with 0–3 unhealthy lifestyle factors and their associations with, respectively, HRQoL, disease activity, physical function, pain, fatigue, anxiety, and depression were performed by analysis of covariance (ANCOVA), adjusted for age and SpA-subgroup, and presented with beta-estimates (β-est) and 95% confidence intervals (CI). Multiple logistic regression analyses were performed, one model with ≥ 2 unhealthy lifestyle factors as dependent variable. To study the impact of HEPA, a model including only patients who reported two unhealthy lifestyle habits (n = 528) and with not fulfilling HEPA recommendations as dependent variable was used. All logistic regression analyses were performed with simple contrast to a reference group for each of the variables and presented as odds ratios (OR) and 95% CI. Age and SpA subgroup were included in all analyses, and all other variables (HRQoL, disease activity, physical function, pain, fatigue, anxiety, and depression) were added separately, and controlled for age and SpA subgroup. All statistical analyses were conducted at the 0.05 significance level. Statistical analyses were performed using SPSS for Windows, version 25 (IBM Corp., Armonk, NY, USA).

**Results**
Out of 1793 patients with SpA (AS, PsA, USpA) who responded to the questionnaire in 2011, 1426 (80%) completed all required information for the lifestyle factors (physical activity, BMI, and tobacco use) and were thus included in the study. Of those, 678 (48%) were men and 748 (52%) were women. Characteristics for patients with AS (n = 433, 40% women), PsA (n = 745, 56% women), and USpA (n = 248, 62% women) are presented in Table 1.

The 367 patients who had incomplete data for any of the studied lifestyle factors, and who therefore were not included in the analyses, had a mean (SD) age of 60 (14) years and more than half were women (58%). As compared to the included SpA population, they had significantly worse quality of life, disease activity, physical function, pain, fatigue, and depression (p ≤ 0.01). In addition, most of the patients with incomplete data on lifestyle factors had not completed the questions for MVPA (78%), as compared to BMI (14%) or tobacco use (smoking [8%]/snuff/snus [22%]).

**Unhealthy lifestyle habits**
Of the total number of included SpA patients (n = 1426), 83% reported having one or more unhealthy lifestyle factors, of which not meeting HEPA recommendations (51%) and being overweight/obese (60%) were the most common ones. Present tobacco usage was reported by 21% of the patients (Table 2). Fewer patients with PsA...
Table 1  Characteristics of patients in each SpA subgroup and for women and men (n = 1426)

| SpA subgroup  | All     | Women   | Men     |
|--------------|---------|---------|---------|
| AS, no       | 433     | 175     | 258     |
| Age, years   | 57.5 (13.3) | 56.0 (13.8) | 58.4 (12.8) |
| Symptom duration, years | 28.7 (13.7) | 25.2 (13.7) | 31.0 (13.3) |
| EQ-SD (0–1)  | 0.68 (0.26) | 0.64 (0.27) | 0.70 (0.25) |
| BASDAI (0–10)| 3.6 (2.2)   | 4.2 (2.2)   | 3.2 (2.2)   |
| BASFI (0–10) | 3.2 (2.6)   | 3.5 (2.6)   | 3.0 (2.5)   |
| Pain (0–10)  | 3.9 (2.5)   | 4.3 (2.4)   | 3.5 (2.5)   |
| Fatigue (0–10)| 4.6 (2.7)   | 5.4 (2.6)   | 4.1 (2.6)   |
| HADs, anxiety (0–21)| 5.5 (4.3) | 6.1 (4.4) | 5.2 (4.2) |
| HADs, depression (0–21)| 4.1 (3.4) | 3.9 (3.2) | 4.2 (3.5) |
| HEPA yes/no, n (%) | 226/207 (52/48) | 74/101 (42/58) | 152/106 (59/41) |
| BMI (kg/m²)  | 25.9 (3.7)  | 25.1 (3.9)  | 26.4 (3.5)  |
| Smoking no/stopped/yes, n (%) | 203/182/48 (47/42/11) | 84/67/24 (48/38/14) | 119/115/24 (46/45/9) |
| Snuff/snus no/stopped/yes, n (%) | 336/45/46 (78/10/11) | 161/5/5 (92/3/3) | 175/40/41 (68/16/16) |
| PsA, no      | 745      | 418      | 327      |
| Age, years   | 59.7 (12.4) | 58.8 (12.8) | 60.9 (11.9) |
| Symptom duration, years | 19.9 (12.5) | 20.2 (13.4) | 19.5 (11.3) |
| EQ-SD (0–1)  | 0.66 (0.24) | 0.63 (0.26) | 0.70 (0.22) |
| BASDAI (0–10)| 4.0 (2.2)   | 4.3 (2.1)   | 3.3 (2.1)   |
| BASFI (0–10) | 3.2 (2.5)   | 3.8 (2.4)   | 2.5 (2.3)   |
| Pain (0–10)  | 4.2 (2.4)   | 4.7 (2.3)   | 3.6 (2.5)   |
| Fatigue (0–10)| 4.9 (2.7)   | 5.5 (2.5)   | 4.1 (2.7)   |
| HADs, anxiety (0–21)| 5.5 (4.3) | 6.2 (4.6) | 4.7 (3.9) |
| HADs, depression (0–21)| 4.2 (3.6) | 4.5 (3.7) | 3.9 (3.4) |
| HEPA yes/no, n (%) | 343/402 (46/54) | 168/250 (40/60) | 175/152 (54/46) |
| BMI (kg/m²)  | 27.1 (4.7)  | 26.8 (5.0)  | 27.4 (4.3)  |
| Smoking no/stopped/yes, n (%) | 291/352/97 (39/47/13) | 147/193/77 (35/46/18) | 144/159/20 (44/49/6) |
| Snuff/snus no/stopped/yes, n (%) | 582/56/80 (78/8/11) | 371/42/1 (89/1/5) | 211/52/59 (65/16/18) |
| USpA, no     | 248       | 155       | 93        |
| Age, years   | 52.9 (12.9) | 52.6 (13.2) | 53.5 (12.3) |
| Symptom duration, years | 19.9 (12.3) | 19.5 (11.9) | 20.5 (13.0) |
| EQ-SD (0–1)  | 0.68 (0.24) | 0.67 (0.23) | 0.70 (0.25) |
| BASDAI (0–10)| 4.0 (2.3)   | 4.3 (2.3)   | 3.5 (2.3)   |
| BASFI (0–10) | 2.9 (2.4)   | 3.3 (2.4)   | 2.3 (2.2)   |
| Pain (0–10)  | 4.1 (2.5)   | 4.4 (2.6)   | 3.7 (2.4)   |
| Fatigue (0–10)| 4.9 (2.9)   | 5.2 (2.8)   | 4.3 (2.8)   |
| HADs, anxiety (0–21)| 5.5 (4.5) | 5.7 (4.5) | 5.2 (4.5) |
| HADs, depression (0–21)| 4.1 (3.9) | 4.1 (3.9) | 4.1 (4.0) |
| HEPA yes/no, n (%) | 128/120 (52/48) | 78/77 (50/50) | 50/43 (54/46) |
| BMI (kg/m²)  | 26.0 (4.5)  | 26.0 (4.8)  | 26.0 (4.1)  |
| Smoking no/stopped/yes, n (%) | 137/83/28 (55/34/11) | 84/51/20 (54/33/13) | 53/32/8 (57/34/9) |
| Snuff/snus no/stopped/yes, n (%) | 211/82/22 (85/3/9) | 141/2/6 (91/1/4) | 70/7/16 (75/7/17) |

Values are mean (SD), unless otherwise indicated

SpA spondyloarthritis, AS ankylosing spondylitis, PsA psoriatic arthritis, USpA undifferentiated spondyloarthritis, EQ-SD EuroQol 5-Dimensions, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, HADs Hospital Anxiety and Depression scale, HEPA health-enhancing physical activity, BMI body mass index

* Utilities calculated by the British time trade-off-based preference set. Missing data: symptom duration: 108 (8%), EQ-SD: 66 (5%), BASDAI: 31 (2%), BASFI: 24 (1.7%), Pain/Fatigue 5 (0.3%), HADs anxiety/depression: 9 (0.6%), Smoking: 5 (0.4%), Snuff: 40 (2.8%)
(13%) as compared to patients with AS (22%) or USpA (20%) \( (p < 0.001) \), reported none of the studied unhealthy lifestyle factors (Fig. 1).

Having one unhealthy lifestyle factor was reported by 40% of the patients, while 37% reported two, and 6% reported three unhealthy lifestyle factors. In the group who reported one unhealthy lifestyle factor \( (n = 569) \), 34% were not currently meeting recommendations for HEPA, 54% were overweight/obese, and 12% were current tobacco users. This resulted in 43% of all patients with SpA reporting \( \geq 2 \) unhealthy lifestyle factors, and with no difference between women and men \( (p = 0.373) \). When stratified into SpA subgroups, a significantly larger group of the patients with PsA reported \( \geq 2 \) unhealthy lifestyle factors (48%), as compared to patients with AS (39%) or USpA (38%), \( p < 0.002 \) (Fig. 1).

When comparing each lifestyle factor on its own, the only statistically significant difference found between the SpA-subgroups was that more patients with PsA reported a BMI \( \geq 25 \text{ kg/m}^2 \) (65%), as compared to patients with AS (56%) or USpA (54%) \( (p = 0.001) \). This was related to that more patients with PsA were obese (women [23%), men [21%]), as compared to patients with AS (women [13%), men [16%]) or USpA (women [13%], men [15%]) \( (p = 0.030/p = 0.003) \) (data not presented).

Comparisons between women and men in each SpA-subgroup showed that HEPA was more frequently reported by men with AS and PsA, as compared to women in each subgroup \( (p \leq 0.001) \), while women with AS and PsA more often reported healthy BMI \( (< 25 \text{ kg/m}^2) \) than men (AS: \( p = 0.001 \), PsA: \( p = 0.007 \)). In AS, fewer women than men were current tobacco users \( (p = 0.061) \). No differences were found between men and women with USpA in any of the lifestyle factors studied (Table 2).

### Associations with physical and mental health
HRQoL, disease activity, physical function, pain, fatigue, anxiety, and depression were negatively associated with a higher number of unhealthy lifestyle factors, adjusted for

### Table 2 Differences in lifestyle factors for all SpA, stratified for SpA-subgroups and men and women

| SpA-subgroup         | All     | Women   | Men     | \( p \) value |
|----------------------|---------|---------|---------|--------------|
| All SpA, no          | 1426    | 748     | 678     |              |
| HEPA yes/no, n (%)   | 697/729 (49/51) | 320/428 (43/57) | 377/301 (56/44) | \( \leq 0.001 \) |
| BMI below/above 25 kg/m\(^2\), n (%) | 565/861 (40/60) | 327/421 (44/56) | 238/440 (35/65) | 0.001 |
| Tobacco yes/no-stopped, n (%) | 299/1127 (21/79) | 146/602 (20/80) | 153/525 (23/77) | 0.158 |
| AS, no               | 433     | 175     | 258     |              |
| HEPA yes/no, n (%)   | 226/207 (52/48) | 74/101 (42/58) | 152/106 (59/41) | 0.001 |
| BMI below/above 25 kg/m\(^2\), n (%) | 189/244 (44/56) | 90/85 (51/49) | 99/159 (38/62) | 0.007 |
| Tobacco yes/no-stopped, n (%) | 83/350 (19/81) | 26/149 (15/85) | 57/201 (22/78) | 0.061 |
| PsA, no              | 745     | 418     | 327     |              |
| HEPA yes/no, n (%)   | 343/402 (46/54) | 168/250 (40/60) | 175/152 (54/46) | \( \leq 0.001 \) |
| BMI below/above 25 kg/m\(^2\), n (%) | 262/483 (35/65) | 168/250 (40/60) | 94/233 (29/71) | 0.001 |
| Tobacco yes/no-stopped, n (%) | 168/577 (23/77) | 95/323 (23/77) | 73/254 (22/78) | 0.896 |
| USpA, no             | 248     | 155     | 93      |              |
| HEPA yes/no, n (%)   | 128/120 (52/48) | 78/77 (50/50) | 50/43 (54/46) | 0.600 |
| BMI below/above 25 kg/m\(^2\), n (%) | 114/134 (46/54) | 69/86 (45/55) | 45/48 (48/52) | 0.554 |
| Tobacco yes/no-stopped, n (%) | 48/200 (19/81) | 25/130 (16/84) | 23/70 (25/75) | 0.097 |

Chi-squared tests were used for group comparisons of proportions for healthy/unhealthy lifestyle factors

| SpA | spondyloarthritis, AS ankylosing spondylitis, PsA psoriatic arthritis, USpA undifferentiated spondyloarthritis, HEPA health-enhancing physical activity, BMI body mass index |

Fig. 1 Bar charts showing proportions of number of unhealthy lifestyle factors (0–3) for SpA subgroups. SpA subgroups (AS, \( n = 433 \), PsA, \( n = 745 \), USpA, \( n = 248 \)). Presented with error bars with 95% CI, \( p < 0.001 \), for all. AS ankylosing spondylitis, PsA psoriatic arthritis, USpA undifferentiated spondyloarthritis
age and SpA-subgroup ($p \leq 0.001$) (Table 3). The results also showed significantly worse outcomes for HRQoL, disease activity, physical function, pain, fatigue, anxiety, and depression, adjusted for age and SpA-subgroup for patients with two or more unhealthy lifestyle factors, compared with those reporting none or one (Table 4).

To explore the impact of physical activity more thoroughly, we also performed separate multivariate logistic regression analyses on the subgroup who reported two unhealthy lifestyle factors ($n = 528$). The results showed that patients who used tobacco and had a BMI $\geq 25$ kg/m$^2$ but fulfilled HEPA recommendations ($n = 79$) reported lower disease activity, better physical function and were less fatigued, as compared with those not fulfilling HEPA recommendations and who either used tobacco or had a BMI $\geq 25$ kg/m$^2$ ($n = 449$), adjusted for age and SpA-subgroup (Table 5).

### Discussion

In this cross-sectional survey of 1426 patients with SpA, only 17% of the patients reported none of the investigated unhealthy lifestyle factors, while a large group (43%) reported two or more unhealthy lifestyle factors, more often patients with PsA, and with no difference between women and men. We also found that having two or more unhealthy lifestyle factors were negatively associated with physical and mental health and that the negative effect on health increased with every added unhealthy lifestyle factor. Another interesting finding was that, in the subgroup with two unhealthy lifestyle factors, patients who fulfilled HEPA recommendations but reported tobacco use and unhealthy BMI had lower disease activity, better physical function, and reported less fatigue as compared to those not fulfilling HEPA and with one other unhealthy lifestyle factor.

Our results are difficult to compare, because, to the best of our knowledge, this is the first study to investigate how a combination of unhealthy lifestyle factors associate

### Table 4 Results from logistic regression analyses for having $\geq 2$ unhealthy lifestyle factors

| Independent variables | $\geq 2$ unhealthy lifestyle factors | $< 2$ unhealthy lifestyle factors | $\geq 2$ unhealthy lifestyle factors | $p$ value |
|-----------------------|-------------------------------------|----------------------------------|-------------------------------------|-----------|
| Age, years            | Mean (SD)                           | OR 95% CI                        | p value                             |
| SpA subgroup          | 58.6 (11.6)                         | 57.3 (14.0)                     | 1.01 (1.00; 1.01)                   | 0.161     |
| AS                    | 1                                  | 1.40 (1.10; 1.78)               | 0.007                               |
| PsA                   | 0.96 (0.70; 1.33)                   | 0.818                            |
| EQ-SD (0–1)$^a$       | 0.62 (0.27)                         | 0.71 (0.22)                     | 0.25 (0.16; 0.39)                   | $\leq 0.001$ |
| BASDAI (0–10)         | 4.4 (2.2)                           | 3.5 (2.1)                       | 1.21 (1.15; 1.27)                   | $\leq 0.001$ |
| BASFI (0–10)          | 3.8 (2.5)                           | 2.7 (2.4)                       | 1.19 (1.14; 1.25)                   | $\leq 0.001$ |
| Pain (0–10)           | 4.6 (2.5)                           | 3.7 (2.4)                       | 1.16 (1.11; 1.22)                   | $\leq 0.001$ |
| Fatigue (0–10)        | 5.3 (2.7)                           | 4.4 (2.7)                       | 1.14 (1.10; 1.19)                   | $\leq 0.001$ |
| HADs anxiety (0–21)   | 6.1 (4.6)                           | 5.1 (4.1)                       | 1.06 (1.03; 1.08)                   | $\leq 0.001$ |
| HADs depression (0–21)| 4.8 (3.8)                           | 3.7 (3.3)                       | 1.09 (1.06; 1.12)                   | $\leq 0.001$ |

Presented with odds ratios (OR) and 95% CI. Age and SpA subgroup were included in all analyses, and all other variables were added separately, and adjusted for age and SpA subgroup. Number of patients included in analyses (range: $n = 1426–1360$)

SpA spondyloarthritis, AS ankylosing spondylitis, PsA psoriatic arthritis, USpA undifferentiated spondyloarthritis, EQ-SD EuroQol 5-dimensions, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, HADs Hospital Anxiety and Depression scale

$^a$ Utilities calculated by the British time trade-off-based preference set. Missing data: EQ-SD: 66 (5%), BASDAI: 31 (2%), BASFI: 24 (1.7%), Pain/Fatigue 5 (0.3%), HADs anxiety/depression: 9 (0.6%)

### Table 3 Number of unhealthy lifestyle factors and associated factors in patients with SpA ($n = 1426$)

| No. unhealthy lifestyle factors | $0$ | $1$ | $2$ | $3$ | $95\%$ CI | $p$ value |
|--------------------------------|-----|-----|-----|-----|----------|-----------|
| EQ-SD (0–1)$^a$                | 0.74 (0.19) | 0.69 (0.23) | 0.63 (0.27) | 0.59 (0.25) | $-0.06$ ($-0.07$; $-0.04$) | $\leq 0.001$ |
| BASDAI (0–10)                  | 2.9 (2.0) | 3.7 (2.2) | 4.4 (2.3) | 4.4 (2.0) | 0.61 (0.47; 0.74) | $\leq 0.001$ |
| BASFI (0–10)                   | 2.0 (2.0) | 3.0 (2.5) | 3.7 (2.5) | 3.9 (2.5) | 0.67 (0.53; 0.82) | $\leq 0.001$ |
| Pain (0–10)                    | 3.1 (2.2) | 4.0 (2.6) | 4.6 (2.7) | 4.6 (2.5) | 0.62 (0.46; 0.77) | $\leq 0.001$ |
| Fatigue (0–10)                 | 3.6 (2.6) | 4.3 (2.6) | 4.9 (2.7) | 5.1 (2.5) | 0.60 (0.43; 0.76) | $\leq 0.001$ |
| HADs anxiety (0–21)            | 5.0 (4.1) | 5.1 (4.2) | 6.0 (4.5) | 6.7 (4.8) | 0.62 (0.35; 0.89) | $\leq 0.001$ |
| HADs depression (0–21)         | 3.4 (3.1) | 3.9 (3.4) | 4.7 (3.6) | 5.5 (4.5) | 0.71 (0.48; 0.93) | $\leq 0.001$ |

Values presented as mean (SD). 0 = no unhealthy lifestyle factors. Analysis of covariance (ANCOVA) with beta-estimates ($\beta$-est) and 95% confidence intervals (CI), and adjustments for age and SpA subgroup

SpA spondyloarthritis, EQ-SD EuroQol 5-dimensions, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, HADs Hospital Anxiety and Depression scale

$^a$ Utilities calculated by the British time trade-off-based preference set. Missing data: EQ-SD: 66 (5%), BASDAI: 31 (2%), BASFI: 24 (1.7%), Pain/Fatigue 5 (0.3%), HADs anxiety/depression: 9 (0.6%)
with various health outcomes in patients with SpA. In the general population, however, studies have found that individuals who adhered to at least one healthy lifestyle factor had a lower risk of hypertension [4], and a protective effect on all-cause cancer and cardiovascular mortality risk [6], as compared to those who adhered to none of the studied lifestyle factors. Most importantly, individuals who adhered to more than one or all of the studied healthy lifestyle factors had an even greater risk reduction [4, 6]. In our study, fewer than two out of ten patients with SpA reported none of the investigated unhealthy lifestyle factors, with no significant statistical difference between women and men. This figure is clearly lower than more recent data in the Swedish population, where half of the women and one-third of the men reported none of the unhealthy lifestyle factors investigated [38]. We also found that almost half of the patients with PsA reported two or more unhealthy lifestyle factors, which is in line with recent findings reported in the Swedish rheumatoid arthritis (RA) population [39], but higher as compared to nearly four out of ten patients with AS or USpA. This is interesting, considering a previous study in which patients with PsA tended to have a higher risk for stroke and acute coronary syndrome, as compared to patients with AS and USpA [12]. However, the risk of CVD is higher in all SpA subgroups as compared to the general population [10–12] and, therefore, as international and national guidelines emphasise, strategic screening for cardiovascular risk factors and, if required, facilitated lifestyle changes in addition to proper medication in all patients with CIA [15, 40], are of utmost importance.

Two or more unhealthy lifestyle factors were associated with worse physical function, worse pain and fatigue, and lower quality of life. This is inversely supported by a study in the general population, where individuals who adhered to a combination of healthy lifestyle factors in midlife were more likely to age healthily, including having good physical and cognitive functioning [41]. Having two or more unhealthy lifestyle factors was also associated with higher anxiety and depression scores. Considering that patients with higher anxiety and depression scores believe that physical overload and physical effort can trigger the disease and provoke flares [42], multidisciplinary interventions to support patients with an unhealthy lifestyle and worsened physical and mental symptoms are of importance. The above also highlights that patients with mental health conditions, fatigue, and multi-morbidity may need additional support to alleviate concerns regarding treatment, and increased time to improve unhealthy lifestyle habits [43].

In the subgroup who reported two unhealthy lifestyle factors, patients who fulfilled HEPA, but used tobacco and were overweight/obese, reported lower disease activity, better physical function, and were less fatigued than those not fulfilling HEPA and who either used tobacco or were overweight/obese. This indicates, that HEPA is not only of great significance to various health outcomes in patients with SpA but is also of value to monitor in the clinical setting. HEPA is also interesting in view of findings in the general population, where unfit individuals had a higher risk of mortality, regardless of BMI [44], and where physical activity modified the relation between sedentary behaviour and CVD [45]. In addition, it has been suggested that CRF is a strong predictor of health outcomes, and physiotherapists are encouraged to test aerobic capacity to improve personalized approaches when prescribing and coaching physical exercise [8].

Lifestyle changes are challenging for everyone and having several, unhealthy lifestyle factors to address can be overwhelming for patients with CIA [46]. From studies in RA, we know that 60–80% of the patients were not interested in discussing their lifestyle with healthcare professionals [47], and that relatively few patients with RA or PsA with known cardiovascular risk factors had made lifestyle modifications to manage the increased

### Table 5
Sub-analyses on patients with two unhealthy lifestyle factors. Results for not fulfilling HEPA recommendations

| Independent variable | Dependent variable | HEPA (n = 79) | No HEPA (n = 449) | No HEPA OR 95% CI | p value |
|----------------------|--------------------|---------------|-------------------|------------------|--------|
| Age, years           |                    | 55.5 (10.7)   | 59.3 (12.0)       | 1.03 (1.01;1.05) | 0.008  |
| SpA subgroup         |                    |               |                   |                  |        |
| AS                   |                    | 1             |                   |                  |        |
| PsA                  |                    | 0.80 (0.45;1.43) |                 | 0.448            |        |
| USpA                 |                    | 0.95 (0.43;2.06) |                 | 0.866            |        |
| EQ-SD (0–1)⁹         |                    | 0.67 (0.25)   | 0.62 (0.28)       | 0.47 (0.17;1.29) | 0.144  |
| BASDAI (0–10)        |                    | 3.9 (2.3)     | 4.5 (2.2)         | 1.13 (1.01;1.26) | 0.027  |
| BASFI (0–10)         |                    | 2.8 (2.4)     | 3.9 (2.5)         | 1.19 (1.06;1.33) | 0.003  |
| Pain (0–10)          |                    | 4.1 (2.7)     | 4.7 (2.5)         | 1.09 (0.99;1.20) | 0.084  |
| Fatigue (0–10)       |                    | 4.8 (3.0)     | 5.4 (2.6)         | 1.10 (1.01;1.21) | 0.031  |
| HADs anxiety (0–21)  |                    | 5.8 (4.9)     | 6.0 (4.5)         | 1.02 (0.96;1.08) | 0.544  |
| HADs depression (0–21) |                | 4.4 (4.2)     | 4.7 (3.5)         | 1.04 (0.97;1.11) | 0.330  |

Logistic regression analyses presented with odds ratio (OR) and 95% CI. Age and SpA subgroup were included in all analyses, and all other variables were added separately and adjusted for age and SpA subgroup. Number of patients included in sub-analyses (range: n = 528–497). HEPA health-enhancing physical activity, SpA spondyloarthropathy, AS anklyosing spondylitis, PsA psoriatic arthritis, USpA undifferentiated spondyloarthropathy, EQ-SD EuroQol 5-dimensions, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, HADs Hospital Anxiety and Depression scale

⁹ Utilities calculated by the British time trade-off-based preference set. Missing data: EQ-SD: 66 (5%), BASDAI: 31 (2%), BASFI: 24 (1.7%), Pain/Fatigue 5 (0.3%), HADs anxiety/depression: 9 (0.6%)
risk, while most reported usage of pharmacological treatment [48]. In contrast to that study, another study found that patients with PsA, who were aware that the disease was associated with additional health risks (43%), were more likely to be non-smokers and tried to follow a low-fat diet [49]. This further emphasises the importance of screening and managing unhealthy lifestyle factors in a combined way, and of personalising approaches when education and support regarding unhealthy lifestyle factors are offered to patients with SpA.

Our overall results support the need for structured, intervention programmes in everyday clinical practice, where cardiovascular risk and multiple unhealthy lifestyle factors are managed. Educational efforts to increase knowledge regarding the effect of different lifestyle factors on health, and individual coaching to patients who want to change behaviour should also be part of interventions offered at all rheumatology clinics. In addition, coordination between team members is important when patients present with several unhealthy lifestyle factors, given that behaviour change will be even more challenging for these patients.

The study has some limitations to consider. Unfortunately, it lacks information on additional lifestyle factors, such as alcohol consumption, sedentary behaviour, and sleep habits, but also detailed information on markers of inflammation and disease activity. Also, the cross-sectional design made causality uncertain, and non-responders may have affected generalizability, regardless of the fact that the response rate was well in line with other questionnaire-based studies [50]. The excluded group (due to incomplete data on lifestyle factors) reported worse physical and mental health than the studied SpA population which may have caused some bias and could have resulted in an underestimation of the impact of unhealthy lifestyle factors on health. Another limitation was that lifestyle factors were self-reported, and therefore may have affected the validity of the study. Even if self-reported information regarding smoking, BMI and physical activity are widely accepted, direct measures, such as aerobic capacity and visceral fat analyses could have added important information and are of interest to address in future studies. A strength of the study was the population-based design, with inclusion of patients from both primary and specialized care. Another strength was the large sample size, enabling us to compare patients in three SpA subgroups and explore differences between women and men.

With regard to ongoing efforts to improve lifestyle habits in both the general population and in patients with rheumatic diseases, and due to the fact that overweight and obesity has increased while physical activity levels and tobacco usage has been more or less unchanged in the overall Swedish population during the time-period, the findings from this study with data captured in 2011, needs to be confirmed in future studies.

Conclusions
To conclude, four out of ten patients with SpA reported two or more unhealthy lifestyle factors, more often patients with PsA, as compared to those with AS or USpA. Having two or more unhealthy lifestyle factors were negatively associated with both physical and mental health and the negative effect on health was greater with every added unhealthy lifestyle. The most common unhealthy lifestyle factor was overweight/obesity, followed by not adhering to recommendations for HEPA. A sub-analysis showed that not adhering to HEPA was associated with worse health outcomes, compared with being obese or using tobacco. In order to promote sustainable health, there is a need for individualized coordinated interventions to screen for a combination of unhealthy lifestyle factors, and to tailor coaching accordingly to support behavioral change.

Abbreviations
ANCOVA: Analysis of covariance; AS: Ankylosing spondylitis; BASDAI: The Bath Ankylosing Spondylitis Disease Activity Index; BASFI: The Bath Ankylosing Spondylitis Functional Index; BMI: Body mass index; CDAI: Chronic inflammatory arthritis; CRF: Cardiorespiratory fitness; CVD: Cardiovascular diseases; EQ-SD-3L: The EuroQol five dimensions, three levels; EULAR: The European Alliance of Associations for Rheumatology; HADS: The Hospital Anxiety and Depression scale; HEPA: Health-enhancing physical activity; HRQoL: Health-related quality of life; ICD-10: The International Classification of Diseases and Related Health Problems, 10th revision; IPAQ: The International Physical Activity Questionnaire; MPA: Moderate-intensity aerobic physical activity; NRS: Numerical rating scale; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis; SHR: Skåne Healthcare Register; SpA: Spondyloarthritis; VPA: Vigorous-intensity aerobic physical activity; WHO: The World Health Organization.

Acknowledgements
The authors would like to acknowledge the SpAScania group for assistance with data extraction, and Jan-Åke Nilsson for statistical support.

Authors’ contributions
All authors participated in the study design, acquisition of data, analysis, and interpretation of data. EM drafted the manuscript and all authors revised, read, and approved the final manuscript.

Funding
Open access funding provided by Lund University. This work was supported by grants from: Region Skåne; Skåne University Hospital; Spenshult Research and Development Centre; the Swedish Rheumatism Association; and the Kock Foundation. The sponsors were not involved in the study design, data collection, data analysis, interpretation of data, or writing of the report.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
Ethical approval was granted by the Regional Ethics Committee in Lund, Sweden (Dnr 301/2007, 406/2008, 2011/547 and 2013/128), and an informed written consent was obtained from all patients, in accordance with the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
Elisabeth Mogard: Consultant for Novartis (unrelated to the present work). Ann Bremander: None declared. Emma Haglund: Consultant for Novartis (unrelated to the present work).

Author details
1 Department of Clinical Sciences Lund, Rheumatology, Skane University Hospital, Lund University, Lund, Sweden. 2 Department of Clinical Sciences Lund, Rheumatology, Faculty of Medicine, Lund University, Lund, Sweden. 3 Spenshult Research and Development Centre, Halmstad, Sweden. 4 Department of Regional Health Research, University of Southern Denmark, Odense, Denmark. 5 Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark. 6 Rydberg Laboratory of Applied Sciences, Halmstad University, Halmstad, Sweden.

Received: 2 January 2022 Accepted: 14 March 2022
Published online: 25 May 2022

References
1. World Health Organization: Cardiovascular diseases. The problem. https://www.who.int/nmh/publications/fact_sheet_cardiovascular_en.pdf. Accessed 9 Dec 2021.
2. World Health Organization: Preventing cancer. http://www.who.int/activities/preventing-cancer. Accessed 9 Dec 2021.
3. World Health Organization: Diabetes. Key facts. http://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed 9 Dec 2021.
4. Lelong H, Blacher J, Baudry J, Adriouch S, Galan P, Fezeu L, et al. Combination of healthy lifestyle factors on the risk of hypertension in a large cohort of French adults. Nutrients. 2019;11:1687.
5. Lacombe J, Armstrong MEC, Wright PL, Foster C. The impact of physical activity and an additional behavioural risk factor on cardiovascular disease, cancer and all-cause mortality: a systematic review. BMC Public Health. 2019;19:900.
6. Petersen KE, Johnsen NF, Olsen A, Albier V, Olsen LX, Dragsted LO, et al. The combined impact of adherence to five lifestyle factors on all-cause, cancer and cardiovascular mortality: a prospective cohort study among Danish men and women. Br J Nutr. 2015;113:849–58.
7. Myers J, McAuley P, Lavié CJ, Despres JP, Arena R, Kokkinos P. Physical activity and cardiorespiratory fitness as major markers of cardiovascular risk: their independent and interwoven importance to health status. Prog Cardiovasc Dis. 2015;57:306–14.
8. Ross R, Blair SN, Arena R, Church TS, Despres JP, Franklin BA, et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American Heart Association. Circulation. 2016;134:e653–99.
9. Myers J, Kokkinos P, Nylen E. Physical activity, cardiorespiratory fitness, and the metabolic syndrome. Nutrients. 2011;9:11652.
10. Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res. 2011;63:550–6.
11. Ogdie A, Yu Y, Haynes K, Love TJ, Malha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326–32.
12. Bengtsson K, Forsblad-d’Elia H, Lie E, Klingberg E, Dehlin M, Exarchou S, et al. Risk of cardiac rhythm disturbances and aortic regurgitation in different spondyloarthritis subtypes in comparison with general population: a register-based study from Sweden. Ann Rheum Dis. 2018;77:541–8.
13. Castaneda S, Nummohamed MT, Gonzalez-Gay MA. Cardiovascular disease in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol. 2016;30:851–69.
14. Eder L, Wu Y, Chandran V, Cook R, Gladman DD. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann Rheum Dis. 2016;75:1680–6.
15. Rudvall E, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–83.
16. Rudvall E, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(11):25–31. https://doi.org/10.1136/ard.2010.133645.
17. Agca R, Heslinga SC, Rollefstad S, Heslinga M, Mctinnes IB, Peters MJ, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76:17–28.
18. Fabre S, Molto A, Dadoun S, Reicn C, Hudry C, Kreis S, et al. Physical activity in patients with axial spondyloarthritis: a cross-sectional study of 203 patients. Rheumatol Int. 2016;36:171–8.
19. Haglund E, Bergman S, Petersson IF, Jacobsson LT, Strombeck B, Bremander A. Differences in physical activity patterns in patients with spondyloarthritis. Arthritis Care Res. 2012;64:1886–94.
20. World Health Organization. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. Technical Report Series, No 854.329. http://apps.who.int/iris/bitstream/handle/10665/182958/WHO_TRS_854.pdf?sequence=1&isAllowed=y. Accessed 9 Dec 2021.
21. Maas F, Arends S, van der Veer E, Wink F, Efde M, Boot MA, et al. Obesity is common in axial spondyloarthritis and is associated with poor clinical outcome. J Rheumatol. 2016;43:383–7.
22. Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res. 2017;69:51–7.
23. Hoigaard P, Glinborg L, Kruse L, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DABIGAB and KEBEO registries. Rheumatology (Oxford). 2016;55:2191–9.
24. Chung HY, Machado P, van der Heijde D, D’Agostino MA, Doulagados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis. 2012;71:809–14.
25. Bremander A, Jacobsson LT, Bergman S, Haglund E, Loefvendahl S, Petersson IF. Smoking is associated with a worse self-reported health status in patients with psoriatic arthritis: data from a Swedish population-based cohort. Clin Rheumatol. 2015;34:579–83.
26. Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol. 2014;41:1357–65.
27. Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, et al. Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. Rheumatology (Oxford). 2014;53:875–81.
28. Mogard E, Bremander A, Lindqvist E, Bergman S. Prevalence of chronic widespread pain in a population-based cohort of patients with spondyloarthritis—a cross-sectional study. BMC Rheumatol. 2018;2:1–7.
29. Haglund E, Bremander AB, Petersson IF, Strombeck B, Bergman S, Jacobsson LT, et al. Prevalence of spondyloarthritis and its subtypes in southern Sweden. Ann Rheum Dis. 2011;70:943–8.
30. The IPAQ group. Guidelines for data processing and analysis of the international physical activity questionnaire (IPAQ)—short and long forms. http://www.ipaq.ki.se. Accessed 9 Dec 2021.
31. Ekelund U, Sepp H, Brage S, Becker W, Jakobi L, Hennings M, et al. Criterion-related validity of the last 7-day, short form of the International Physical Activity Questionnaire in Swedish adults. Public Health Nutr. 2006;9:258–65.
32. Socialstyrelsen. Frågor om dina levnadsvanor. https://www.socialstyrelsen.se/globalassets/sharepointdokument/dokument-webb/nationella-ritkliner/levnadsvanor-fragor-om-levnadsvanor.pdf. Accessed 15 Feb 2022.

33. Rausch Osthoff AK, Niedermann K, Braun J, Adams J, Brodin N, Dagfinrud H, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77:1251–60.

34. Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H. Validity of EuroQol—a generic health status instrument—in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br J Rheumatol. 1994;33:655–62.

35. Garret S, Jenkinson T, Kennedy LG, Whitelock H, O’Hea J, Mallorie P, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91.

36. Garret S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.

37. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.

38. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to defining disease status in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.

39. Karstensen JK, Primdahl J, Andersson MLE, Christensen JR, Bremander A. Lifestyle factors in patients with rheumatoid arthritis—a cross-sectional study on two Scandinavian cohorts. Clin Rheumatol. 2021. https://doi.org/10.1007/s10067-021-05905-2.

40. Svensk Reumatologisk Förening: Kardiovaskulär primärprevention vid inflammatorisk reumatisk sjukdom. https://svenskreumatologi.se/wp-content/uploads/2020/03/sammanfattnings-av-bakgrundsdokumentation-primarprevention-avsende-kardiovaskularr-sjukdom.pdf. Accessed 9 Dec 2021.

41. Atallah N, Adjibade M, Lelong H, Herceberg S, Galan P, Assmann KE, et al. How healthy lifestyle factors at midlife relate to healthy aging. Nutrients. 2018;10:854.

42. Gossec L, Berenbaum F, Chauvin P, Hudry C, Cukierman G, de Chalus T, et al. Development and application of a questionnaire to assess patient beliefs in rheumatoid arthritis and axial spondyloarthritis. Clin Rheumatol. 2018;37:2649–57.

43. Edelar L, Nikiphorou E, Fragoulis GE, Jagnocco A, Haines C, Bakkers M, et al. 2019 EULAR recommendations for the generic core competences of health professionals in rheumatology. Ann Rheum Dis. 2020;79:53–60.

44. Barry VW, Baruth M, Beets MW, Durstine JL, Liu J, Blair SN. Fitness vs. fatness on all-cause mortality: a meta-analysis. Prog Cardiovasc Dis. 2014;56:382–90.

45. Ekelund U, Brown WJ, Steene-Johannessen J, Fagerland MW, Owen N, Powell KE, et al. The associations of sedentary behaviour with cardiovascular disease mortality and cancer mortality differ by physical activity level? A systematic review and harmonised meta-analysis of data from 850 060 participants. Br J Sports Med. 2019;53:886–94.

46. Malm K, Bremander A, Arvidsson B, Andersson ML, Bergman S, Larsson I. The influence of lifestyle habits on quality of life in patients with established rheumatoid arthritis—a constant balancing between ideality and reality. Int J Qual Stud Health Well-Being. 2016;11:30534.

47. Malm K, Bergman S, Bremander A, Larsson I, Andersson MLE, group B. Discussions of lifestyle habits as an integral part of care management: a cross-sectional cohort study in patients with established rheumatoid arthritis in Sweden. Rheumatol Adv Pract. 2019;3:ki039.

48. Sinnathurai P, Capon A, Buchbinder R, Chand V, Henderson L, Lassere M, et al. Cardiovascular risk management in rheumatoid and psoriatic arthritis: online survey results from a national cohort study. BMC Rheumatol. 2018;2:25.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.